and human data to transfo Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024. In addition ...

Appointment of José Antonio Alas brings more than 30 years of biotech expertise, including global business development, ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

“The problem with the Alzheimer’s group is they were very co-opted,” said Peter J. Whitehouse, MD, PhD, a professor of ...

Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute ...

Seven Bridges Specialty, a specialty pharmacy services innovator, is proud to announce the appointment of Steve Granzyk as President and Chief Executive Officer. Steve brings over three decades of ...

The Harrison County Community Foundation recently announced Samantha Carr as the recipient of the 2025 Lilly Endowment ...

EBENSBURG — Jace Casses erupted for a career-high 50 points, including five 3-pointers, to spark Bishop Carroll Catholic to an 87-64 victory over Richland in high school boys basketball action on ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,020.00. Akash Tewari’s rating is based ...

Huge crowds have come out to Chinatown for Lunar New Year as new political faces take office. She made the look her own with ...